Treatment of Central Centrifugal Cicatricial Alopecia and Frontal Fibrosing Alopecia Using Deucravacitinib for 48 Weeks

What this Trial Is About

Researchers are evaluating deucravacitinib as a treatment for two types of scarring hair loss conditions Central Centrifugal Cicatricial Alopecia CCCA and Frontal Fibrosing Alopecia FFA. This open-label, phase 2 clinical trial will include about 20 adults diagnosed with moderate-to-severe forms of these conditions. The study is conducted by the Icahn School of Medicine at Mount Sinai and aims to assess changes in various inflammatory and fibrotic markers in the scalp over time. Participants will receive deucravacitinib orally at a dose of 12 mg once daily for 48 weeks. The study groups consist of individuals diagnosed with either CCCA or FFA. Treatment begins at the baseline visit Day 0 and continues daily without a placebo comparison. The full treatment period lasts 48 weeks, during which participants will be monitored for biological and clinical changes related to their hair loss. Throughout the study, participants will attend scheduled visits to evaluate changes in immune and fibrotic markers in the scalp at weeks 24 and 48. Clinical assessments will include hair loss severity scores, quality of life indexes, itch severity scales, and hair density and thickness measurements. Safety and adherence will be monitored through medical histories, physical exams, and laboratory tests. The total commitment for participants is approximately 48 weeks of treatment and follow-up assessments.

Deucravacitinib in the Treatment of Cicatricial Alopecias